Most Read Articles
Audrey Abella, 14 Sep 2017
The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.

Dialysis increases mortality risk in elderly hip fracture patients

03 Oct 2017
Nearly 40,000 kidney patients were reported in Malaysia since last year.

Dialysis appears to raise the risk of mortality in elderly patients with hip fracture, reveals a new retrospective cohort study from Taiwan.

Investigators retrieved relevant medical data of 61,346 elderly patients with first incidence of hip fracture. Of these, 997 were undergoing dialysis while the remaining 60,349 were not. Matching for age and sex at a 1:5 ratio resulted in the final study sample size of 5,982 individuals, of which 997 were dialysis patients while 4,985 were not.

Compared with matched controls, patients on dialysis were significantly more likely to have femoral neck fracture (p<0.001) and be treated with arthroplasty (p<0.001). Mortality rate was also significantly higher in the dialysis group than in the nondialysis group (91 vs 61 percent; p<0.001). A total of 3,935 mortality events were reported.

Unadjusted Cox proportional models showed that dialysis significantly increased the risk of mortality in both male and female patients at 0 to 3 months (hazard ratio [HR], 2.58; 95 percent CI, 2.13 to 3.13; p<0.001), 3 to 12 months (HR, 2.95; 2.48 to 3.51; p<0.001), 1 to 6 years (HR, 2.84; 2.55 to 3.15; p<0.001) and 6 to 10 years (HR, 2.39; 1.94 to 2.93; p<0.001) after fracture.

Adjusting for fracture site, comorbidities, sex and age did not attenuate the significant impact of dialysis on mortality at 0 to 3 months (HR, 2.36 1.94 to 2.87; p<0.001), 3 to 12 months (HR, 2.49; 2.09 to 2.98; p<0.001), 1 to 6 years (HR, 2.70; 2.43 to 3.00; p<0.001) and 6 to 10 years (HR, 2.32; 1.89 to 2.86; p<0.001) after the fracture. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 14 Sep 2017
The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.